QUANTIFICATION OF HYPERTHERMIA PRETREATMENT PROTOCOL

本项目致力于开发一种定量热疗装置。 治疗计划方案。初步实验表明，一种独特的 稳态温升与SAR的比值之间存在着关系 和有效的组织导热系数(这是热损失的原因 对传导和血液流动都有影响)。然而，目前还没有可用的方法 用于评估治疗中的散热机制 音量。这一开发工作将侧重于改进测量 超声波仪和方法学 微波热疗输送系统。增强版的功能 热扩散探头将扩展到产生测量 体内多个组织部位的温度、热导率和SAR 基于多传感器和导管传感器的治疗量研究 探测器。“特征加热曲线”，与有效热有关 对局部组织加热的传导性，将开发适用于一系列 哈佛-麻省理工学院热疗中心和 达纳·法伯癌症研究所。在临床环境中，这些曲线， 结合有效导热系数的前处理测量， 可以预测实现治疗加热的能力，或者是否 介入组织的过度加热很可能是治疗- 限制。这将立即对热疗产生好处：a 组织热清除的标准测量将使客观 施肥者和方式的比较和评价；空间 有效导热系数的分布可以用来作为 为肿瘤量身定做SAR分布的量化基础；以及 显然，无法治疗的区域可以被识别出来，以提供 取消治疗，因更换敷贴器或方式，或 随后使用更合适的涂抹器进行治疗。

This project addresses the development of a quantitative hyperthermia therapy planning protocol. Preliminary experiments show that a distinctive relation exists between the ratio of steady-state temperature rise to SAR and effective tissue thermal conductivity (which accounts for heat loss due to both conduction and blood flow). However, there is no available method for assessing the thermal dissipative mechanisms within the treatment volume. This development effort will focus on improving measurement instrumentation and methodology for application to both ultrasound and microwave hyperthermia delivery systems. The capabilities of the Enhanced Thermal Diffusion Probe will be extended to yield measurements of temperature, thermal conductivity, and SAR at multiple tissue sites within a treatment volume through development of Multi-Sensor and Catheter Sensor probes. "Characteristic heating curves," relating effective thermal conductivity to local tissue heating, will be developed for a range of hyperthermia applicators at the Harvard-MIT Hyperthermia Center and the Dana Farber Cancer Institute. In the clinical setting, these curves, combined with pre-treatment measurements of effective thermal conductivity, can predict the ability to achieve therapeutic heating, or whether excessive heating of intervening tissues is likely to be treatment- limiting. This will be of immediate benefit to hyperthermia therapy: a standard measure of tissue thermal clearance will enable objective comparison and evaluation of applicators and modalities; the spatial distribution of effective thermal conductivity can be used as a quantitative basis for tailoring the SAR distribution to the tumor; and clearly untreatable regions can be identified to provide the rationale for canceling therapy, for a change of applicator or modality, or for subsequent treatment with a more appropriate applicator.